/QURE
QURE Stock - uniQure N.V.
Healthcare|BiotechnologyNASDAQ
$23.99+0.25%
+$0.06 (+0.25%) • Dec 19
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.46
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.96
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+160.1%upside
Target: $62.40
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for QURE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$23.75 – $24.23
TARGET (TP)$62.40
STOP LOSS$22.07
RISK/REWARD1:20.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.59
52W High$71.50
52W Low$7.76
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $27.12M | $15.84M | $106.48M | $524.00M | $37.51M |
| Gross Profit | $8.79M | $2.21M | $103.14M | $499.03M | $-84,886,000 |
| Gross Margin | 32.4% | 14.0% | 96.9% | 95.2% | -226.3% |
| Operating Income | $-184,294,000 | $-282,871,000 | $-143,159,000 | $310.62M | $-125,426,000 |
| Net Income | $-239,556,000 | $-308,478,000 | $-126,789,000 | $329.59M | $-125,024,000 |
| Net Margin | -883.4% | -1947.1% | -119.1% | 62.9% | -333.3% |
| EPS | $-4.92 | $-6.47 | $-2.71 | $7.17 | $-2.81 |
Company Overview
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Visit WebsiteRating Distribution
Strong Buy
1
17%
Buy / Outperform
3
50%
Hold / Neutral
2
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
4 Bullish2 Neutral/Bearish
Price Targets
$21
Average Target
↓ 11.6% Downside
Now
$8
Low
$21
Average
$38
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 4th 2025 | William Blair | Downgrade | Market Perform | - |
| August 14th 2025 | Mizuho | Upgrade | Outperform | $30 |
| April 1st 2025 | Chardan Capital Markets | Resumed | Buy | $38 |
| December 10th 2024 | Raymond James | Upgrade | Strong Buy | - |
| October 10th 2024 | Raymond James | Resumed | Outperform | $20 |
| February 29th 2024 | Goldman | Downgrade | Neutral | $8 |
| December 19th 2023 | Mizuho | Downgrade | Neutral | $10← $52 |
Earnings History & Surprises
QUREBeat Rate
58%
Last 19 quarters
Avg Surprise
+1.9%
EPS vs Estimate
Beats / Misses
11/8
Last 12 quarters
Latest EPS
$-1.38
Q4 2025
EPS Surprise History
Q1 24
+0.6%
$-1.53vs$-1.54
Q2 24
-3.8%
$-1.36vs$-1.31
Q3 24
+6.5%
$-1.16vs$-1.24
Q4 24
+18.8%
$-0.91vs$-1.12
Q1 25
-150.0%
$-1.50vs$-0.60
Q2 25
+23.4%
$-0.82vs$-1.07
Q3 25
+22.5%
$-0.69vs$-0.89
Q4 25
-62.4%
$-1.38vs$-0.85
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | $-0.93 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.85 | $-1.38 | -62.4% | ✗ MISS |
Q3 2025 | Jul 29, 2025 | $-0.89 | $-0.69 | +22.5% | ✓ BEAT |
Q2 2025 | May 9, 2025 | $-1.07 | $-0.82 | +23.4% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.60 | $-1.50 | -150.0% | ✗ MISS |
Q4 2024 | Nov 5, 2024 | $-1.12 | $-0.91 | +18.8% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-1.24 | $-1.16 | +6.5% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-1.31 | $-1.36 | -3.8% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-1.54 | $-1.53 | +0.6% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-1.49 | $-1.88 | -26.2% | ✗ MISS |
Q3 2023 | Aug 1, 2023 | $2.97 | $-1.44 | -148.5% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-1.02 | $-1.63 | -59.8% | ✗ MISS |
Q1 2023 | Feb 27, 2023 | $-0.89 | $0.15 | +116.9% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-1.11 | $-1.02 | +8.1% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.96 | $-0.84 | +12.5% | ✓ BEAT |
Q2 2022 | May 2, 2022 | $-0.67 | $-1.00 | -49.3% | ✗ MISS |
Q1 2022 | Feb 25, 2022 | $-0.81 | $0.17 | +121.0% | ✓ BEAT |
Q4 2021 | Oct 25, 2021 | $-1.00 | $-0.79 | +21.0% | ✓ BEAT |
Q3 2021 | Jul 26, 2021 | $2.96 | $8.51 | +187.5% | ✓ BEAT |
Q2 2021 | May 10, 2021 | $-0.89 | $-0.91 | -2.2% | ✗ MISS |
Latest News
Stifel Maintains Buy on uniQure, Lowers Price Target to $40
➖ NeutralBenzinga•Dec 11, 2025, 01:30 PM•Also:
Mizuho Maintains Outperform on uniQure, Lowers Price Target to $33
➖ NeutralBenzinga•Dec 9, 2025, 01:44 PM
Reported Sunday, HEMGENIX Five-Year HOPE-B Results Show 36.1% Mean Factor IX Activity And ~90% Lower Bleeds Versus Lead-In Prophylaxis
📈 PositiveBenzinga•Dec 8, 2025, 08:23 AM
Chardan Capital Maintains Buy on uniQure, Maintains $53 Price Target
📈 PositiveBenzinga•Dec 4, 2025, 06:46 PM
uniQure stock falls after FDA's notes on pre application of AMT-130
📉 NegativeSeeking Alpha•Dec 4, 2025, 02:00 PM
uniQure shares are trading lower after the company that in the FDA conveyed that data submitted from the Phase I/II studies of AMT-130 are currently unlikely to provide the primary evidence to support a BLA submission.
📉 NegativeBenzinga•Dec 4, 2025, 01:54 PM
Uniqure Said FDA Deems AMT-130 Phase I/II Data Unlikely To Support BLA Submission; Company Plans Urgent Follow-Up Meeting With FDA In Q1 2026
📉 NegativeBenzinga•Dec 4, 2025, 12:10 PM
Wells Fargo Maintains Overweight on uniQure, Lowers Price Target to $60
➖ NeutralBenzinga•Nov 12, 2025, 03:21 PM
Chardan Capital Maintains Buy on uniQure, Maintains $53 Price Target
📈 PositiveBenzinga•Nov 11, 2025, 01:13 PM
Leerink Partners Maintains Outperform on uniQure, Lowers Price Target to $60
➖ NeutralBenzinga•Nov 10, 2025, 09:18 PM
CORRECTION: UniQure Q3 EPS $(1.38) Misses $(0.90) Estimate, Sales $3.701M Miss $5.243M Estimate
📉 NegativeBenzinga•Nov 10, 2025, 02:45 PM
uniQure Q3 EPS $(1.85) Misses $(0.90) Estimate, Sales $3.701M Miss $5.243M Estimate
📉 NegativeBenzinga•Nov 10, 2025, 12:10 PM
Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $38
➖ NeutralBenzinga•Nov 4, 2025, 05:05 PM
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $45
➖ NeutralBenzinga•Nov 4, 2025, 04:51 PM
uniQure shares are trading lower after HC Wainwright lowered its price target on the stock from $110 to $70. Also, William Blair downgraded the stock from Outperform to Market Perform.
📉 NegativeBenzinga•Nov 4, 2025, 01:56 PM
William Blair Downgrades uniQure to Market Perform
📉 NegativeBenzinga•Nov 4, 2025, 12:18 PM
HC Wainwright & Co. Maintains Buy on uniQure, Lowers Price Target to $70
➖ NeutralBenzinga•Nov 4, 2025, 11:52 AM
Chardan Capital Maintains Buy on uniQure, Lowers Price Target to $53
📈 PositiveBenzinga•Nov 3, 2025, 09:32 PM
uniQure stock falls after FDA feedback on gene therapy application
📉 NegativeSeeking Alpha•Nov 3, 2025, 03:59 PM
uniQure shares are trading lower after the company announced that it believes that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control may be adequate to provide the primary evidence in support of a BLA submission.
📉 NegativeBenzinga•Nov 3, 2025, 01:36 PM
Frequently Asked Questions about QURE
What is QURE's current stock price?
uniQure N.V. (QURE) is currently trading at $23.99 per share. The stock has moved +0.25% today.
What is the analyst price target for QURE?
The average analyst price target for QURE is $62.40, based on 1 analyst.
What sector is uniQure N.V. in?
uniQure N.V. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is QURE's market cap?
uniQure N.V. has a market capitalization of $1.30 billion, making it a small-cap company.
Does QURE pay dividends?
No, uniQure N.V. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
EWTX
Edgewise Therapeutics, Inc.
$25.55
Mkt Cap: $2.7B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
GPCR
Structure Therapeutics Inc.
$64.94
Mkt Cap: $3.7B
MESO
Mesoblast Limited
$19.48
Mkt Cap: $2.5B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
OCUL
Ocular Therapeutix, Inc.
$12.56
Mkt Cap: $2.2B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
VRDN
Viridian Therapeutics, Inc.
$31.92
Mkt Cap: $2.6B
Explore stocks similar to QURE for comparison